➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson

Last Updated: June 16, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for GDC-0349

Email this page to a colleague

« Back to Dashboard

What is the drug development status for GDC-0349?

GDC-0349 is an investigational drug.

There have been 178 clinical trials for GDC-0349. The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2010.

The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, and Lymphoma. The leading clinical trial sponsors are Genentech, Inc., National Cancer Institute (NCI), and Hoffmann-La Roche.

Recent Clinical Trials for GDC-0349
Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSLKazia Therapeutics LimitedPhase 2
Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSLLakshmi NayakPhase 2
A Phase 2 Study of Venetoclax in Combination With Low-dose HHT, G-CSF, and AZA as First-line Treatment for Newly Diagnosed Elderly AML Patients Unfit for Intensive ChemotherapyShanghai Jiao Tong University School of MedicinePhase 2

See all GDC-0349 clinical trials

Clinical Trial Summary for GDC-0349

Top disease conditions for GDC-0349
Top clinical trial sponsors for GDC-0349

See all GDC-0349 clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.